BT-267 has been engineered for high brain permeability, potency, and selectivity—attributes believed to be critical for disease-modifying LRRK2 inhibition in Parkinson's disease. "The emerging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results